Sublicensees
TheraVectys continues to strengthen its collaborations and to develop new partner relationships to deliver potential life-saving innovative vaccines and therapeutics to improve the lives of people around the world.
Astellas
The Company and Astellas Pharma Inc., a Japanese corporation, entered a non-exclusive worldwide license for the treatment, prevention, and management of cancer, including solid tumor and hematologic cancers, using a cellular therapeutic vaccine incorporating the Company’s proprietary lentiviral vector DNA flap technology.
Jinwei Bio
Jinwei Bio was granted an exclusive license to the use of the non-integrative lentiviral vector technology to develop a prophylactic and therapeutic Hepatitis B Vaccine, HBV, in China and its territories. During 2018, Jinwei Bio was granted a license to develop personalized neo-antigen vaccines for the treatment of cancer. During 2019, Jinwei was granted a license to develop a prophylactic and therapeutic TB vaccine for tuberculosis.
Merck
The Company entered into a license agreement with Immune Design Corp. (IDC) pursuant to which IDC received a field limited, non-exclusive license for oncology uses to certain current and future intellectual property rights owned, controlled and licensed by the Company relating to lentiviral vector technologies. Immune Design Corp was later acquired by Merck for $300 million.
Novasep
The company expanded its existing agreement with Novasep to add certain additional patents and patent applications included under the Company’s Institute Pasteur License Agreement, and to extend the scope of the original license field. The NVS Group is an international supplier of manufacturing services and specialized technologies for the life sciences industry.